Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use

Mandeep Singh, Thomas L SchwartzSUNY Upstate Medical University, Psychiatry Department, Syracuse, NY, USABackground: Vilazodone is the latest approved antidepressant available in the United States. Its dual mechanism of action combines the inhibition of serotonin transporters while simultaneously pa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singh M, Schwartz TL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/b60b4fd3c3b345fba41818b2a048eb6a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b60b4fd3c3b345fba41818b2a048eb6a
record_format	dspace
spelling	oai:doaj.org-article:b60b4fd3c3b345fba41818b2a048eb6a2021-12-02T00:14:55ZClinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use1176-63281178-2021https://doaj.org/article/b60b4fd3c3b345fba41818b2a048eb6a2012-03-01T00:00:00Zhttp://www.dovepress.com/clinical-utility-of-vilazodone-for-the-treatment-of-adults-with-major--a9553https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Mandeep Singh, Thomas L SchwartzSUNY Upstate Medical University, Psychiatry Department, Syracuse, NY, USABackground: Vilazodone is the latest approved antidepressant available in the United States. Its dual mechanism of action combines the inhibition of serotonin transporters while simultaneously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in serotonin facilitation across the brain&#39;s serotonergic pathways, which has been termed by the authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI.Objective: The authors to review laboratory, animal model data, and human trial data to synthesize a working theory regarding the mechanism of antidepressant action of this agent and regarding its potential for additional indications.Methods: A MEDLINE and Internet search was conducted and the resultant evidence reviewed.Results: Vilazodone has randomized, controlled empirical data which has garnered it an approval for treating major depressive disorder. It combines two well-known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants are published, the efficacy data for vilazodone appears comparable to other known antidepressants, with associated gastrointestinal side effects similar to serotonin selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, but potentially with a lower incidence of sexual side effects and weight gain.Discussion: As a new option for the treatment of major depressive disorder, vilazodone, due to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate or have not responded to previous antidepressant monotherapies. Additionally, its use may extend to the treatment of other mental health conditions similar to those treated by serotonin selective reuptake inhibitors.Keywords: major depressive disorder, vilazodone, antidepressantsSingh MSchwartz TLDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2012, Iss default, Pp 123-130 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Singh M Schwartz TL Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
description	Mandeep Singh, Thomas L SchwartzSUNY Upstate Medical University, Psychiatry Department, Syracuse, NY, USABackground: Vilazodone is the latest approved antidepressant available in the United States. Its dual mechanism of action combines the inhibition of serotonin transporters while simultaneously partially agonizing serotonin-1a (5-HT1A) receptors. This combined activity results in serotonin facilitation across the brain&#39;s serotonergic pathways, which has been termed by the authors as that of a serotonin partial agonist and reuptake inhibitor, or SPARI.Objective: The authors to review laboratory, animal model data, and human trial data to synthesize a working theory regarding the mechanism of antidepressant action of this agent and regarding its potential for additional indications.Methods: A MEDLINE and Internet search was conducted and the resultant evidence reviewed.Results: Vilazodone has randomized, controlled empirical data which has garnered it an approval for treating major depressive disorder. It combines two well-known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants are published, the efficacy data for vilazodone appears comparable to other known antidepressants, with associated gastrointestinal side effects similar to serotonin selective reuptake inhibitor and serotonin norepinephrine reuptake inhibitor antidepressants, but potentially with a lower incidence of sexual side effects and weight gain.Discussion: As a new option for the treatment of major depressive disorder, vilazodone, due to its unique SPARI mechanism of action, may hold promise for patients who cannot tolerate or have not responded to previous antidepressant monotherapies. Additionally, its use may extend to the treatment of other mental health conditions similar to those treated by serotonin selective reuptake inhibitors.Keywords: major depressive disorder, vilazodone, antidepressants
format	article
author	Singh M Schwartz TL
author_facet	Singh M Schwartz TL
author_sort	Singh M
title	Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
title_short	Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
title_full	Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
title_fullStr	Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
title_full_unstemmed	Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
title_sort	clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/b60b4fd3c3b345fba41818b2a048eb6a
work_keys_str_mv	AT singhm clinicalutilityofvilazodoneforthetreatmentofadultswithmajordepressivedisorderandtheoreticalimplicationsforfutureclinicaluse AT schwartztl clinicalutilityofvilazodoneforthetreatmentofadultswithmajordepressivedisorderandtheoreticalimplicationsforfutureclinicaluse
_version_	1718403885500989440

Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use

Ejemplares similares